AEM (SGX:AWX)'s 3Q20 PATMI of SGD24.3m (+77.4% y-o-y, +27.1% q-o-q) was ahead of our and consensus expectations.
We raise AEM's FY20E PATMI by 3%, on the back of AEM's positively revised FY20 revenue guidance of SGD500-520m from SGD480-500m previously. However, our FY21-22E earnings are largely unchanged pending FY21E revenue guidance in Jan '21.
Maintain BUY and Target Price of SGD5.05 (14x FY21E P/E).
Key Customer Drives Strong 3Q20
AEM's 3Q20 revenue rose 93% y-o-y to SGD161.8m, on the back of Intel's demand for tools, consumables and services.
AEM will spend SGD2mil on R&D in 4Q20 for future projects, and have hired more staff to boost core engineering capabilities.
AEM's Long Term Growth Drivers Unchanged
AEM remains positive on long-term growth prospects. The rollout of 5G enables increased complexity in mission-critical applications. This has resulted in unprecedented challenges in chip testing. Heterogeneous packaging is also becoming mainstream, as traditional Moore's law scaling faces limitations.
VLSI Research expects system level test (SLT) to grow 4.4x faster than wafer sort and functional test in 2020-24, as SLT is beneficial in overcoming limitations of current design-for-test techniques, which leave millions of transistors untested.
Opportunities to Buy the Dips May Emerge
AEM expects seasonality patterns to normalise to 2Q/3Q being peak quarters, and 1Q and 4Q being lulls in any given year. This contrasts what was observed in 4Q19/1Q20, where these were the strong quarters within 2019/2020 respectively. This normalisation may imply difficult y-o-y revenue comparisons in 4Q20/1Q21.
At the same time, AEM's share price has risen 125% in the past 12 months. As such, we see risks of lacklustre AEM's share price performance until Jan-21 when FY21 revenue guidance is provided, and this may provide opportunities for investors to accumulate on dips.
Key risk is if Intel faces steeper than expected market share loss, which may temper the pace of equipment orders to AEM.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....